Form 8-K Editas Medicine, Inc. For: Oct 22
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Editas Medicine (EDIT) PT Lowered to $9 at Wells Fargo
October 23, 2024 6:36 AM EDTWells Fargo analyst Yanan Zhu lowered the price target on Editas Medicine (NASDAQ: EDIT) to $9.00 (from $27.00) while maintaining a Overweight rating.
The analyst comments "EDIT today reported preclinical data for its in vivo HSPC editing program and also provided BD and financial... More
